Comparison of the Effect of Sintilimab Combined with Albumin Binding Type Paclitaxel and Gemcitabine in the Treatment of Squamous Non-small Cell Lung Cancer
Objective To compare the effect of Sintilimab combined with albumin binding type paclitaxel and gecitabine in the treatment of squamous non-small cell lung cancer(sqNSCLC).Methods The clinical data of 76 patients with sqNSCLC lung cancer admitted to Anyang Cancer Hospital from June 2021 to June 2023 were retrospectively analyzed,and they were divided into two groups according to different treatment schemes.Among them,32 patients who were treated with Sintilimab combined with albumin binding type paclitaxel were included in T group,and 44 patients who were treated with Sintilimab combined with gecitabine were included in G group.The clinical efficacy,serum tumor markers[squamous cell carcinoma antigen(SCC),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)]levels,adverse drug reactions and progression-free survival(PFS)were compared between the two groups.Results After treatment,there was no statistical significant difference in objective response rate(ORR),disease control rate(DCR),PFS and median PFS between the G and T groups(P＞0.05).After treatment,the SCC,CYFRA21-1 and CEA of patients in both G and T groups decreased compared to before treatment(P＜0.05).But there was no statistical significant difference between the two groups(P＞0.05).During the treatment process,there was no statistical significant difference in the incidence of gastrointestinal reactions,bone marrow suppression,hyponatremia,immune related pneumonia,and thyroid dysfunction between G and T groups patients(P＞0.05).However,the incidence of liver and kidney dysfunction in T group was lower than that in G group,and the difference was statistically significant(P＜0.05).Conclusion The clinical efficacy of Sintilimab combined with albumin binding type paclitaxel is similar to that of Sintilimab combined with gemcitabine in the treatment of sqNSCLC,but the incidence of liver and kidney dysfunction in the Sintilimab combined with albumin binding type paclitaxel regimen is lower.
squamous non-small cell lung cancerSintilimabalbumin binding type paclitaxelgecitabine
NETL
NSTL
万方数据
